MedicureTSXV:MPH 64 OCF Margin % is -22.96% as of Mar. 2026. GuruFocus rates TSXV:MPH with a GF Score™ of 64/100 and a GF Value™ of C$1.55 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Medicure ranks worse than 81.54% on this metric.
The historical rank and industry rank for Medicure's OCF Margin % or its related term are showing as below:
TSXV:MPH'
s OCF Margin % Range Over the Past 10 Years
Min: -72.58 Med: 7.11 Max: 80.8
Current: -9.71
During the past 13 years, the highest OCF Margin % of Medicure was 80.80%. The lowest was -72.58%. And the median was 7.11%.
TSXV:MPH's OCF Margin % is ranked worse than 81.54% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs TSXV:MPH: -9.71
Medicure OCF Margin % Related Terms
Medicure OCF Margin % Historical Data
* Premium members only.
The historical data trend for Medicure's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Medicure's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicure (TSXV:MPH) has a OCF Margin % of -22.96% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medicure and its competitors. According to the industry distribution chart, Medicure ranks #782 out of 959 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is Medicure's OCF Margin % too high?
Medicure's current OCF Margin % is -22.96%. Based on the distribution chart, Medicure ranks #782 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicure has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medicure's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #782 out of 959 companies for OCF Margin %. This places Medicure in the lower half of its industry. The industry median OCF Margin % is 9.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medicure and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicure's current OCF Margin % is -22.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Modestly Undervalued. The stock's GF Value™ is C$1.55, compared to a current price of C$1.28 — trading 17.4% below its estimated fair value. The current OCF Margin % is -22.96%. Medicure's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current OCF Margin % is -22.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (TSXV:MPH) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be undervalued.
The current stock price of C$1.28 is trading 17.4% below its estimated GF Value™ of C$1.55.
GuruFocus considers Medicure to be Modestly Undervalued.
Key valuation signals for TSXV:MPH:
OCF Margin %: -22.96%
GF Value™: C$1.55 vs. price of C$1.28 (17.4% below fair value)
No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
64GF Score
Get the complete analysis for TSXV:MPH
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:MPH has been successfully added to your 
